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2Summary29
CTL are associated with protective immunity against disease caused by equine30
herpesvirus-1 (EHV-1). However, the EHV-1 target proteins for CTL are poorly defined.31
This limits the development of vaccine candidates designed to stimulate strong CTL32
immunity. Here, classical CTL assays using lymphocytes from horses of three defined33
MHC class I types that experienced natural infection with EHV-1, and a modified vaccinia34
virus construct containing an EHV-1 gene encoding the Immediate Early (IE) protein are35
reported. Horses homozygous for the Equine Leukocyte Antigen (ELA) A2 haplotype, but36
not the ELA-A5 haplotype, made MHC-restricted CTL responses against the IE protein.37
Previously, horses homozygous for the ELA-A3 haplotype also mounted CTL responses38
against the IE protein. Both haplotypes are common in major horse breeds, including the39
Thoroughbred. Thus, the IE protein is an attractive candidate molecule for future studies of40
T-cell immunity to EHV-1 in the horse.41
42
3Short Communication43
Equine herpesvirus-1 (EHV-1) can cause late gestation abortion in pregnant mares and44
respiratory and neurological disease in all equids (Ma et al., 2013; Minke et al., 2004).45
Current vaccines against EHV-1 contain either live attenuated or killed virus, and both46
types provide partial clinical and virological protection (Minke et al., 2004). However,47
periodic abortion storms and outbreaks of neurological disease highlight the need for48
improved vaccines. Protection against EHV-1 in horses is associated with high titres of49
neutralising antibody (Hannant et al., 1993; Heldens et al., 2001) and high frequencies of50
CTLs (Allen, 2008; Kydd et al., 2003; O'Neill et al., 1999). Ideal vaccines might consist of51
defined antigens which can stimulate protective cellular and humoral immunity in all horses52
and thus eliminate the negative effects of viral proteins which modulate the host’s immune53
response (Ambagala et al., 2005; Griffin et al., 2010; van der Meulen et al., 2006),54
including down-regulation of MHC class I (Rappocciolo et al., 2003; Said et al., 2012).55
56
To develop novel vaccines against EHV-1 that stimulate protective cellular immune57
responses, it is necessary to identify conserved and immune-dominant viral proteins and58
determine the distribution of MHC class I molecules within and between horse breeds.59
MHC class I molecules act as restriction elements that present viral peptides to the antigen60
specific receptors on T-cells. The equine MHC region has been defined using serological61
assays (Lazary et al., 1988) and molecular techniques that have taken advantage of62
resources of the Horse Genome Project (Gustafson et al., 2003; Tallmadge et al., 2005;63
2010). MHC typing using microsatellites (Tseng et al., 2010) has confirmed earlier64
serological studies (Antczak et al., 1986) which indicated that within the Thoroughbred65
breed, a limited number of stable MHC haplotypes (Equine Leukocyte Antigens, ELA-A2,66
A3, A5 and A10) represent the majority of the genetic diversity in this region of the67
4genome. The economic importance of the Thoroughbred justifies a closer examination of68
the genetic basis of immunity in this breed.69
70
To date, although high frequencies of CTL precursors are associated with reduced clinical71
signs (Allen, 2008; Kydd et al., 2003), the only CTL target protein which has been72
identified for EHV-1 is the immediate early (IE) protein, which is encoded by gene 6473
(Soboll et al., 2003). Epitopes of this protein are presented by the B2 allele of the ELA-A374
haplotype (Kydd et al., 2006), which is also known as ELA-A3.1 (Tallmadge et al., 2005).75
Vaccination of ELA-A3 ponies which expressed the B2 allele with a construct which76
expressed the IE protein resulted in the stimulation of interferon gamma+ lymphocytes in77
peripheral blood, which are associated with CTL activity (Paillot et al., 2006) and a78
reduction in cell associated viraemia (Soboll et al., 2010), indicating partial virological79
protection.80
81
This study aimed to assess the EHV-1 IE protein as a CTL target in horses of defined82
MHC haplotypes, which had been exposed to a virulent strain of EHV-1 during a field83
outbreak. The preliminary data suggests that the IE protein acted as a CTL target in two84
mares carrying the ELA-A2 MHC haplotype, but not in a mare homozygous for the ELA-A585
haplotype. This data enhances our knowledge of CTL target proteins for EHV-1, a finding86
critical to the rational development of novel vaccines.87
88
Animals: The mares used in this study (Table 1) were members of an experimental herd at89
Cornell University, United States of America that experienced a natural outbreak of90
disease caused by EHV-1. One additional mare (Esther) was located at the Animal Health91
5Trust, United Kingdom. This mare was hyper-immune to EHV-1 following previous92
experimental infections with strain Ab4 and was thus used as a donor of positive control93
lymphocytes, due to the high frequencies of blood CTLs. All mares had known ELA94
haplotypes, which were common in Thoroughbreds, as determined previously by95
serological typing: the Cornell mares were all homozygous for the specified haplotype96
(Table 1). All animals were managed according to their host institution’s animal care97
criteria and national regulations.98
99
Blood samples: PBMCs collected by jugular venepuncture were isolated at Cornell100
University by density gradient centrifugation over Ficoll®, washed, and re-suspended at101
108/ml in Dulbecco’s modified Eagle’s medium supplemented with 10% (v:v) heat102
inactivated fetal calf serum, 2mM L-glutamine, HEPES buffer, 100u/ml penicillin and103
100g/ml streptomycin. Cells were transported to the United Kingdom at ambient104
temperature over 48 hours under a government permit. On arrival, cells were re-counted105
and either used immediately in induction cultures or alternatively cryopreserved in liquid106
nitrogen as described previously (Allen et al., 1995) and thawed as required. Due to the107
difficulty of harvesting and transporting such large numbers of cells internationally, each108
experiment was performed once only. Viability in all samples, as determined by Trypan109
blue exclusion was >90%110
111
CTL Assay: An EHV-1 specific assay of CTL activity was performed as described112
previously (Allen et al., 1995; Kydd et al., 2006). Effector cells were induced with live EHV-113
1 and screened against a variety of autologous or heterologous target cells that were114
either EHV-1 infected, mock infected, or infected with a modified vaccinia virus construct115
(NYVAC) expressing EHV-1 gene 64, which encodes the IE protein (see Kydd et al., 2006;116
6Paillot et al., 2006 for construct details). The optimum m.o.i. for infection of target cells by117
the construct was determined by titration (m.o.i. 5, 2 and 1) and screened against effector118
lymphocytes from a mare (Esther) with an ELA-A3/x haplotype that had been hyper-119
infected with EHV-1. Results were expressed as percent specific lysis, calculated120
according to a standard formula (experimental c.p.m – spontaneous c.p.m.) / (c.p.m. total121
release – c.p.m. spontaneous release) x100. Data were expressed as the mean of 3122
replicates.123
124
EHV-1 infection was confirmed in the Cornell horses by the local diagnostic laboratory,125
based on clinical signs, virus isolation and complement fixing (CF) antibody titres. One126
mare (AM) displayed transient ataxia. The remaining Cornell mares had high titres of CF127
antibody (>1:80), regardless of vaccination status.128
129
The first aim of this study was to identify horses of well-characterized MHC class I types130
with high levels of EHV-1 specific CTL activity: these were used for future screening131
against target cells presenting only the EHV-1 IE protein encoded by gene 64. Six of132
seven horses tested had detectable levels of virus specific CTL activity, with low levels of133
lysis (<6%) against mock-infected autologous target cells (Fig. 1). One mare (G, ELA-A2)134
had insufficient effector cells and virus specific lysis of <12% at 100:1 effector to target135
ratio (data not shown) and so was discarded from future experiments. The remaining six136
mares, all had high levels of virus specific lysis when tested on infected autologous cells137
(range >29 - 80.7% at effector to target ratios of 100:1). The effector CTL were also tested138
against virus infected target cells from the other mares. High levels of target cell lysis139
(>20%) were observed only when the CTL and target cells carried the same MHC type,140
thus demonstrating classical MHC restricted lysis.141
7142
Having identified mares with detectable CTL activity, additional PBMC from three mares143
with representative MHC class I haplotypes (FTM and Y2K both ELA-A2 and FW ELA-A5)144
were collected and transported as described previously for further experiments designed145
to determine the role of the IE protein as a CTL target. For logistical reasons, the second146
sample was collected one year later and thus measurement of EHV-1 specific CTL activity147
was repeated at that time.148
149
To determine the optimum m.o.i. of NYVAC-gene 64 with which to infect target cells,150
effector CTL from an experimental mare, Esther, which carried the ELA-A3 haplotype were151
used. This A3/x mare was hyperimmune to EHV-1 and had CTL activity against the IE152
protein. This titration demonstrated that an m.o.i. of 2 was sufficient to produce detectable153
target cell lysis (Fig. 2(a)).154
155
Next, the CTL from three mares, Y2K and FTM (both ELA-A2) and FW (ELA-A5) were156
tested against target cells infected with NYVAC-gene 64 at an m.o.i. of 2 (Fig. 2). All157
mares showed CTL activity against autologous virus infected target cells, but not against158
mock-infected targets. For the NYVAC-gene 64 infection, insufficient autologous target159
cells were available from the mare Y2K (ELA-A2); therefore Y2K effectors were tested160
against target cells from FTM (ELA-A2). Effector CTL from the two ELA-A2 mares lysed161
ELA-A2+ target cells infected with NYVAC-gene 64, but not NYVAC-gene 64 infected162
targets of the ELA-A3 haplotype. Mare FW (ELA-A5) failed to lyse either ELA-A3+ or ELA-163
A5+ cells infected with NYVAC-gene 64. Cumulatively, this data suggests that the IE164
8protein provides peptides recognized by CTL in EHV-1 primed horses of the ELA-A2 MHC165
class I haplotype but not the ELA-A5 haplotype.166
167
This study provides new data on the viral proteins that stimulate CTL activity in horses168
after natural infection with EHV-1. The use of a unique herd of MHC homozygous horses169
permitted association between CTL response and MHC haplotype. Previous studies170
indicated that the EHV-1 IE protein encoded by gene 64 is the source of peptides that bind171
to the ELA-A3.1 gene (alias B2) of the ELA-A3 haplotype (Kydd et al., 2006; Soboll et al.,172
2003). Here the data suggest that the IE protein also contains a peptide(s) that is173
presented by a MHC class I gene of the ELA-A2 haplotype, but not of the ELA-A5174
haplotype. This information adds to our understanding of the targets of cellular immune175
responses against this important equine viral pathogen. Further study will be required to176
identify which ELA-A2 MHC class I gene presents peptide(s) from the IE protein. Five177
MHC class I genes have been identified in the ELA-A2 haplotype, with two showing178
properties of classical, polymorphic, antigen presenting molecules (Tallmadge et al.,179
2010).180
181
CTL target proteins have been identified in other herpesviruses. For example, in varicella182
zoster virus tegument proteins encoded by Open Reading Frames (ORFs) 4, 10, 62, 63183
and gI act as CTL targets (Arvin et al., 1991; Bergen et al., 1991; Sadzot-Delvaux et al.,184
1997). In human cytomegalovirus, phosphoprotein 65, a major late matrix protein, is185
recognised by CTL from HLA-A2 individuals (Kern et al., 2002; McLaughlin-Taylor et al.,186
1994; Wills et al., 1996). In bovine herpesvirus type 1 (BHV-1), CTL clones lysed BHV-1187
infected target cells in a genetically restricted, virus specific manner (Splitter et al., 1988)188
9although whether gB, gC and gD are the targets is controversial (Hart et al., 2011; Levings189
& Roth, 2013).190
191
In the horse, CTL target proteins and their genetic restriction elements have also been192
identified for equine infectious anaemia virus (EIAV). These include Gag p26 which is193
presented by the ELA-A5.1 and ELA-A9, and peptides of the Env protein which are ELA-194
A1 restricted (Zhang et al., 1998). Detailed studies of the interaction between viral195
epitopes and MHC class I alleles have revealed a remarkable degree of complexity. In196
horses, there is clearly sub-haplotypic variation (Chung et al., 2003) and this may be a197
reflection of polymorphism at alleles encoded by classical MHC class I loci. Additionally,198
horse MHC haplotypes appear to have differing numbers of classical MHC class I genes, a199
feature not found in humans or mice (Tallmadge et al., 2010). This diversity by genes200
expressed on classical MHC class I loci is consistent with the host’s need to generate201
immune responses and to retain the capacity for flexibility in defence against attack by202
pathogens, but complicates vaccine design.203
204
Despite this diversity of MHC class I loci and alleles, there is also evidence that certain205
viral proteins behave in an immunodominant fashion and stimulate CTL from horses206
carrying several different MHC haplotypes. For example, studies of CTL targets in six207
horses that had been infected with EIAV showed that Gag gene products, which encode208
matrix and capsid proteins, were consistently recognised by various serological MHC class209
I haplotypes. However, no identical peptides within these proteins were consistently210
recognised (Zhang et al., 1998). The elegant work of Mealey et al., (2006) showed that211
within the ELA-A1 haplotype, a single amino acid difference in the 2 domain between the212
MHC class I genes 7-6 and 141 resulted in the ineffective presentation of the Gag GW-12213
10
peptide by gene 141. As a consequence, there was a functional alteration in the ability of214
horses carrying the 141 gene to recognise peptides. Modelling suggested that the215
mechanism was related to the 114-Gag Gw12 complex not being recognised by the T cell216
receptor. In the ELA-A3 serological haplotype, two subtypes, A3.1 and A3.2 have been217
revealed with functional differences, namely only ponies with A3.1 recognised the IE218
protein as a CTL target (Soboll et al., 2003). These subtle yet important functional219
differences need further investigation if subunit vaccines are to become practical in an220
outbred population.221
222
In the current study, the degree of lysis of target cells infected with NYVAC–gene 64 was223
consistently lower than that of target cells infected with EHV-1 virus. Soboll et al. (2003)224
reported a similar phenomenon using single gene products. In the MHC homozygous225
horses studied here, the lower CTL activity to the IE protein is probably a reflection of the226
single target protein presented. The equine CTL response to EHV-1 is undoubtedly227
complex and will include recognition of peptides derived from different EHV-1 proteins.228
229
In summary, the current data in EHV-1 infected mares with defined MHC class I230
haplotypes suggests that peptides of the IE protein are presented by an allele(s) of the231
ELA-A2 serological haplotype, but not ELA-A5. The IE protein therefore acts as a CTL232
target protein in two MHC class I haplotypes, ELA-A2 and ELA-A3.1, which are common in233
the Thoroughbred breed, thereby strengthening the argument for considering its inclusion234
in future novel vaccines.235
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Figure Legends250
Figure 1. MHC restriction of CTL killing of EHV-1-infected target cells. CTL from 6251
MHC homozygous horses (1 ELA-A5 (a), 2 ELA-A2 (b, c), and 3 ELA-A3 (d, e, f) were252
tested against EHV-1 infected target cells of each of the three MHC haplotypes, plus mock253
infected autologous control cells. Genetically restricted, virus specific CTL activity was254
detectable in all mares as demonstrated by lysis of virus infected target cells from mares255
which shared the same haplotype. Levels of lysis were low in autologous, mock infected256
and heterologous target cells collected from mares which did not share the same257
haplotype.258
259
Figure 2. The EHV-1 IE protein is a peptide donor for horses of the ELA-A2 and260
ELA-A3 haplotypes, but not for ELA-A5. CTL activity in effector lymphocytes tested261
against NYVAC-gene 64 infected target cells. a) Titration of NYVAC-gene 64 m.o.i. in262
target cells from a mare (Esther) with A3/x haplotype. b & c) Two ELA-A2 homozygous263
horses showing CTL effector activity against target cells expressing the IE protein encoded264
by EHV-1 gene 64. d) An ELA-A5 homozygous horse that showed CTL effector activity265
against target cells infected with whole EHV-1 virus, but not cells that expressed only the266
IE protein. Target cells were as follows: inf = EHV-1 infected; m= mock infected; g64 =267
infected with NYVACC-gene 64 at m.o.i. 2.268
269
270
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393
Table 1. Details of horses used as blood donors for CTL assays. ELA = Equine Leukocyte394
Antigen; CF = Complement Fixing antibody; V= vaccinated; NV = non-vaccinated; n/d =395
not done.396
397
Horse Age ELA Vaccination **Reciprocal CF antibody titre398
(years) serological status versus399
haplotype* EHV-1 EHV-4400
------------------------------------------------------------------------------------------------------------------------401
G 13 A2 NV 640 640402
Y2K 5 A2 V 320 320403
FTM 11 A2 V 80 10404
CP 17 A3 NV 80 80405
AM 4 A3 V 20 40406
BT 12 A3 NV 320 160407
FW 14 A5 V 320 160408
Esther 13 A3/x NV n/d n/d409
410
*Homozygous unless stated otherwise411
**Samples collected on single occasion as part of the outbreak’s diagnostic investigation412
413
17
414
415
18
FIGURE 2.416
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